Wells Fargo Securities chief equity strategist Christopher Harvey says that while the news of improvement on the coronavirus vaccine front is optimistic, he is seeing the country slow down as it comes out of its malaise.
The Massachusetts modern biotechnology company launched Phase 3 of its coronavirus vaccine test on Monday.
Moderna plans to enroll 30,000 US participants.
MODERNA RECEIVES ANOTHER US $ 472M PRIZE.
There is still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Modern, will actually protect participants.
| Heart | Security | Latest | Change | Change% |
|---|---|---|---|---|
| MRNA | MODERN INC. | 73.21 | -2.12 | -2.81% |
The Proof Needed: Volunteers won’t know if they’re getting the real shot or a fictionalized version. After two doses, scientists will closely monitor which group experiences more infections as they go about their daily routines, especially in areas where the virus is still spreading uncontrollably.
A pharmacist gives Jennifer Haller, left, the first injection in the first-stage safety study clinical trial of a potential vaccine for COVID-19, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle. (AP Photo / Ted S. Wa
Moderna is working with the NIH and the Advanced Biomedical Research and Development Authority to develop its vaccine as part of Operation Warp Speed, the Trump administration’s effort to identify and accelerate the most effective coronavirus vaccines.
The drug maker announced Sunday that it received an additional $ 472 million through BARDA to help develop its potential vaccine.
Moderna’s shares rose in mid-July after positive results from the company’s “Phase 1” study of its vaccine candidate mRNA-1273 COVID-19.
Associated Press contributed to this report.
GET FOX BUSINESS ON THE MOVE BY CLICKING HERE
